Page last updated: 2024-10-25

debrisoquin and Lymphoma

debrisoquin has been researched along with Lymphoma in 1 studies

Debrisoquin: An adrenergic neuron-blocking drug similar in effects to GUANETHIDINE. It is also noteworthy in being a substrate for a polymorphic cytochrome P-450 enzyme. Persons with certain isoforms of this enzyme are unable to properly metabolize this and many other clinically important drugs. They are commonly referred to as having a debrisoquin 4-hydroxylase polymorphism.

Lymphoma: A general term for various neoplastic diseases of the lymphoid tissue.

Research Excerpts

ExcerptRelevanceReference
"101 white British adults with Hodgkin's disease or non-Hodgkin's lymphoma were phenotyped for acetylation status using dapsone and for oxidation status with debrisoquine prior to treatment."3.67Acetylation and oxidation phenotypes in malignant lymphoma. ( Harper, PG; Philip, PA; Rogers, HJ, 1987)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19901 (100.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Philip, PA1
Rogers, HJ1
Harper, PG1

Other Studies

1 other study available for debrisoquin and Lymphoma

ArticleYear
Acetylation and oxidation phenotypes in malignant lymphoma.
    Cancer chemotherapy and pharmacology, 1987, Volume: 20, Issue:3

    Topics: Acetylation; Adult; Aged; Dapsone; Debrisoquin; Female; Hodgkin Disease; Humans; Lymphoma; Lymphoma,

1987